Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Dec;12(6):4635-4642.
doi: 10.3892/ol.2016.5268. Epub 2016 Oct 17.

Bevacizumab, pemetrexed and carboplatin in first-line treatment of non-small cell lung cancer patients: Focus on patients with brain metastases

Dimitra Stefanou  1 , Sofia Stamatopoulou  1 , Antigoni Sakellaropoulou  1 , Gavriil Akakios  1 , Marina Gkiaouraki  1 , Despina Gkeka  1 , Maria Prevezanou  1 , Alexandros Ardavanis  1
Affiliations

Bevacizumab, pemetrexed and carboplatin in first-line treatment of non-small cell lung cancer patients: Focus on patients with brain metastases

Dimitra Stefanou et al. Oncol Lett. 2016 Dec.

Abstract

Data concerning bevacizumab plus pemetrexed plus carboplatin as first-line treatment for patients with non-squamous non-small cell lung cancer (NSCLC) with or without brain metastases (BM) are lacking. The present study analyzed the efficacy and safety of this combination as induction therapy, followed by maintenance therapy with bevacizumab plus pemetrexed in non-squamous NSCLC patients with or without BM. Treatment-naïve patients with advanced non-squamous NSCLC and an Eastern Cooperative Oncology Group performance status score of 0-2 were eligible. Treatment consisted of carboplatin (area under the curve of 5), pemetrexed (500 mg/m2) and bevacizumab (15 mg/kg) every 3 weeks for 6 cycles. Responders and patients with stable disease received maintenance therapy with bevacizumab plus pemetrexed until disease progression, which was evaluated every 3 cycles, or unacceptable toxicity. Kaplan-Meier median progression-free survival (PFS) and overall survival (OS) times were the primary endpoints, and safety was the secondary endpoint. In total, 39 patients, aged 44-78 years (median, 60 years), were treated; 11 (28.2%) of whom presented with BM. The majority of patients (56.4%) completed 6 cycles of induction therapy, and 26 patients continued on to maintenance therapy. The median PFS time was 8.2 months [95% confidence interval (CI), 7.05-9.35] and the median OS time was 14.0 months (95% CI, 8.46-19.54). Median PFS and OS times did not differ significantly between patients with or without BM (log rank (Mantel-Cox): PFS, P=0.748 and OS, P=0.447). The majority of patients (76.9%) did not experience adverse events during treatment. Overall, bevacizumab plus pemetrexed plus carboplatin as induction therapy, followed by bevacizumab plus pemetrexed as maintenance therapy was effective and well tolerated in advanced NSCLC, whether brain metastases were present or not.

Keywords: bevacizumab; brain metastases; carboplatin; carcinoma; chemotherapy; non-small cell lung cancer; pemetrexed.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Kaplan-Meier progression-free survival analysis by subgroup of patients with or without brain metastases at diagnosis.
Figure 2.
Figure 2.
Kaplan-Meier overall survival analysis by subgroup of patients with or without brain metastases at diagnosis.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–E386. doi: 10.1002/ijc.29210. - DOI - PubMed
    1. Atlas of cancer mortality in the European union and the European Economic Area: 1993–1997. IARC Sci Publ. 2008:1–259. - PubMed
    1. Besse B, Adjei A, Baas P, Meldgaard P, Nicolson M, Paz-Ares L, Reck M, Smit EF, Syrigos K, Stahel R, et al. 2nd ESMO consensus conference on lung cancer: Non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. Ann Oncol. 2014;25:1475–1484. doi: 10.1093/annonc/mdu123. - DOI - PubMed
    1. NCCN: National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology, corp-author. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf Non-Small Cell Lung Cancer. Version I. 2015
    1. National Cancer Institute, corp-author. PDQ® Non-Small Cell Lung Cancer Treatment. Bethesda, MD: National Cancer Institute; Accessed Nov 26, 2014.